Yeung, Jenny;
Liao, Aiyin;
Shaw, Matthew;
Silva, Soraia;
Vetharoy, Winston;
Rico, Diego Leon;
Kirby, Ian;
... Amrolia, Persis J; + view all
(2024)
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.
Molecular Therapy
10.1016/j.ymthe.2024.03.032.
(In press).
![[thumbnail of Amrolia_Anti-CD45 PBD Mol Therapy Accepted 3-23.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Amrolia_Anti-CD45 PBD Mol Therapy Accepted 3-23.pdf Access restricted to UCL open access staff until 28 March 2025. Download (343kB) |
Abstract
Stem cell gene therapy and hematopoietic stem cell transplantation (SCT) and stem cell gene therapy require conditioning to ablate the recipient’s hematopoietic stem cells (HSC) and create a niche for gene-corrected/donor HSCs. Conventional conditioning agents are non-specific, leading to off-target toxicities, resulting in significant morbidity and mortality. We developed tissue-specific anti-human CD45 antibody-drug conjugates (ADCs), using rat IgG2b anti-human CD45 antibody clones YTH24.5 and YTH54.12, conjugated to cytotoxic pyrrolobenzodiazepine (PBD) dimer payloads with cleavable (SG3249) or non-cleavable (SG3376) linkers. In vitro, these ADCs internalized to lysosomes for drug release, resulting in potent and specific killing of human CD45+ cells. In humanized NSG mice, the ADCs completely ablated human HSCs without toxicity to non-hematopoietic tissues, enabling successful engraftment of gene-modified autologous and allogeneic human HSCs. The ADCs also delayed leukemia onset and improved survival in CD45+ tumor models. These data provide proof-of-concept that conditioning with anti-human CD45-PBD ADCs allows engraftment of donor/gene-corrected HSC, with minimal toxicity to non-hematopoietic tissues. Our anti-CD45-PBDs or similar agents could potentially shift the paradigm in transplantation medicine that intensive chemo/radiotherapy is required for HSC engraftment after gene therapy and allogeneic SCT. Targeted conditioning both improve the safety and minimize late-effects of these procedures which would greatly increase their applicability.
| Type: | Article |
|---|---|
| Title: | Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant |
| Location: | United States |
| DOI: | 10.1016/j.ymthe.2024.03.032 |
| Publisher version: | http://dx.doi.org/10.1016/j.ymthe.2024.03.032 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | CD45; conditioning; SCTgene therapy; antibody-drug conjugate; leukemia |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10190063 |
Archive Staff Only
 |
View Item |
